Standard BioTools Inc. filed an amended Current Report on Form 8-K to include the full Share and Asset Purchase Agreement as Exhibit 2.1, previously summarized in a filing dated July 28, 2026. The agreement outlines the acquisition by Multiplex Bio Inc. of Standard BioTools' mass cytometry business. This transaction is part of broader strategic moves involving the Treeline transaction, for which a registration statement on Form S-4 was filed on July 20, 2026. Both transactions require stockholder approval and are subject to various closing conditions. The filing serves to provide investors with the definitive contractual terms regarding the disposition of the mass cytometry business. Standard BioTools Inc. operates in the biotechnology industry, developing instruments and reagents for genomic analysis.
